China’s revised Regulations for the Implementation of the Drug Administration Law will take effect in May 2026. The new regulations provide significant updates to strengthen lifecycle regulation while supporting pharmaceutical innovation. The following are the most important changes that are affecting the regulatory landscape.
- Change of clinical trial sponsor
The new regulations introduce a mechanism for transferring clinical trial sponsorship during an ongoing study, along with a 20-working-day review period for applications to change a clinical trial sponsor. This provides greater flexibility for licensing transactions, co-development arrangements, and strategic partnerships, enabling companies to adjust commercial strategies without restarting trials.
- Accelerated approval pathways
The new regulations reinforce expedited pathways for drugs addressing urgent clinical needs. Eligible drug registration applications may utilise the Breakthrough Therapy Designation, Conditional Approval, Priority Review, and Special Approval procedures to expedite market authorisation. These pathways are increasingly aligned with clinical value, allowing faster patient access while maintaining regulatory oversight.
- Recognition of overseas data
Overseas clinical trial data may now be used to support drug registration in China, provided they meet the national drug regulatory authority and ethnic-relevance requirements. This reduces duplication of clinical studies and supports global development programmes, particularly for international multi-centre clinical trials (IMCTs) and China entry strategies.
- Market exclusivity
The new regulations grant market exclusivity periods to paediatric medicines and orphan drugs. Eligible paediatric medicines may be granted a market exclusivity period of up to two years, and orphan drugs may be granted up to seven years, subject to certain conditions. The specific conditions and methods for granting these periods will be formulated by the State Council’s drug regulatory authorities. Market exclusivity will terminate if the Marketing Authorisation Holder (MAH) fails to fulfil its supply obligations.
- Data protection
The regulation establishes a formal data protection framework for medicinal products, covering independently generated and undisclosed trial data submitted by MAHs. This includes data supporting products containing novel chemical entities and other eligible categories. The protection period may extend up to six years from marketing authorisation. During this period, such data cannot be used or relied upon by other parties for commercial purposes. This development provides clearer protection for R&D investment and signals stronger regulatory support for innovation.
- Expanded MAH responsibilities
Marketing Authorisation Holders (MAHs) are expected to take full responsibility across the product lifecycle, covering R&D, manufacturing oversight, and post-marketing safety. This includes establishing and maintaining effective quality management and pharmacovigilance systems, assessing the impact of manufacturing changes, and conducting post-marketing evaluation. If MAHs fail to adequately monitor product quality, efficacy, or adverse reactions, or do not fulfil post-marketing evaluation requirements, re-registration may be refused when the approval period expires.
- Manufacturing flexibility
The new regulations introduce more flexible manufacturing arrangements, including a segmented production model under defined circumstances. MAHs may engage qualified manufacturers to conduct segmented production for innovative drugs with specialised technical requirements, as well as urgently needed clinical drugs for rare diseases or public health emergencies. The framework also provides a legal basis for the conditional use of certain commercial-scale batches produced prior to approval. Once marketing authorisation is granted, eligible batches that meet release requirements may be supplied, supporting earlier market readiness while maintaining regulatory control over quality.
The revised regulations position China as a more accessible and commercially attractive market for foreign pharmaceutical companies and life sciences investors. Acceptance of overseas clinical data and strengthened expedited pathways support more efficient global development strategies and reduce time to market. At the same time, the introduction of a defined data protection regime, together with formalised market exclusivity mechanisms for certain product categories, improves visibility on intellectual property protection and commercial returns. This provides greater confidence for both investment and early market entry decisions. In parallel, increased flexibility in clinical trial sponsorship and clearer allocation of responsibilities under the MAH framework make it easier to structure licensing and partnership arrangements across different stages of development. Taken together, these changes are expected to support continued growth in cross-border investment, licensing, and strategic collaboration involving China.
Author: Wai Theng Lee, Clinical Research Partnerships Manager
